Shelton’s NanoViricides has nominated a clinical drug candidate for the treatment of Covid-19, bringing it a step closer to conducting human clinical trials.
The candidate, NV-CoV-1-R, combines the company’s nanoviricides platform with remdesivir, the anti-viral drug that has been approved for emergency use to treat the coronavirus.